Cardiovascular Pharmacogenetic Genotyping Panel
Related Gene(s): ABCG2, CYP2C (rs12777823), CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP4F2, F2, F5, SLCO1B1, VKORC1
Related Medication(s): Please see the Pharmacogenetic Medication and Gene Panels table for further information
Our Cardiovascular Pharmacogenetic Genotyping Panel is designed to detect allelic and copy number variants in 9 genes that are clinically actionable or informative on 23 medications. This test is intended to help physicians make therapeutic decisions for these selected medications that are indicated for patients with cardiovascular disorders and which can have interindividual response variability. In addition, this panel also reports on thrombophilia risk by interrogating the F2 and F5 genes.
For this test, targeted genotyping of functional sequence variants is performed using the Agena Biosciences platform and copy number variants interrogated for the CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes by MLPA.
- Blood: One 5-10 mL ACD tube (yellow top) and two 5-10 mL EDTA tubes (lavender top)
- Saliva: Saliva specimens are accepted in Oragene DNA (OG-500) kits by DNA Genotek
- Ship at room temperature
- 10-14 days from receipt of specimen
Cardiovascular Pharmacogenetic Genotyping Panel Clinical Information Sheet